Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Data on drug-coated balloon (DCB) treatment in the context of multivessel coronary artery disease (CAD) are limited.
Objectives: The purpose of this study was to investigate the impact of DCB-based treatment on percutaneous coronary intervention for multivessel CAD.
Methods: A total of 254 patients with multivessel disease successfully treated with DCBs or in combination with drug-eluting stents (DES) were retrospectively enrolled (DCB-based group) and compared with 254 propensity-matched patients treated with second-generation DES from the PTRG-DES (Platelet Function and Genotype-Related Long-Term Prognosis in Drug-Eluting Stent-Treated Patients With Coronary Artery Disease) registry (n = 13,160) (DES-only group). Major adverse cardiovascular events (MACE) comprised cardiac death, myocardial infarction, stroke, stent thrombosis, target vessel revascularization, and major bleeding at 2 years.
Results: Baseline clinical characteristics were comparable between the groups. In the DCB-based group, 34.3% of patients were treated with DCBs only and 65.7% were treated with the DES hybrid approach. The number of stents and total stent length were significantly reduced by 65.4% and 63.7%, respectively, in the DCB-based group compared with the DES-only group. Moreover, the DCB-based group had a lower rate of MACE than the DES-only group (3.9% and 11.0%; P = 0.002) at 2-year follow-up. The DES-only group had a higher risk for cardiac death and major bleeding.
Conclusions: The DCB-based treatment approach showed a significantly reduced stent burden for multivessel percutaneous coronary intervention and led to a lower rate of MACE than the DES-only treatment. This study shows that DCB-based treatment approach safely reduces stent burden in multivessel CAD, and improved long-term outcomes may be expected by reducing stent-related events. (Impact of Drug-Coated Balloon Treatment in De Novo Coronary Lesion; NCT04619277).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jcin.2022.10.049 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug-Coated Balloon-Based Versus Drug-Eluting Stent-Only Treatment for Large Vessel Coronary Artery Disease.
Catheter Cardiovasc Interv
August 2025
Department of Cardiology, Ulsan Medical Center, Ulsan, South Korea.
Background: Drug-coated balloon (DCB) treatment has shown outcomes comparable to drug-eluting stent (DES) in small vessel coronary disease. However, evidence for its application in large vessel coronary artery disease (CAD) remains limited.
Aims: This study evaluated the clinical impact of DCB-based percutaneous coronary intervention (PCI) in patients with large vessel CAD.
Long-Term Effectiveness of a Stent-Less Strategy With Drug Coated Balloon in Coronary Artery Disease: 3-Year Follow-Up of a Prospective All-Comers Observational Study.
Clin Cardiol
August 2025
Clinical Trials Unit, Centre Hospitalier la Rochelle, la Rochelle, France.
Introduction: Drug-eluting stent (DES) angioplasty is the gold standard treatment for coronary lesions. Drug-coated balloon (DCB) is an option for in-stent restenosis, and has also shown promise for small-calibre coronary artery disease. We evaluated the 3-year effectiveness of a decision algorithm for percutaneous coronary intervention (PCI) that favoured a stent-less strategy (SLS) in primary angioplasty.
View Article and Find Full Text PDFDrug-coated balloon-based versus drug-eluting stent-only treatment for single de novo diffuse coronary lesions.
Rev Esp Cardiol (Engl Ed)
July 2025
Division of Cardiology, Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, Republic of Korea.
Introduction And Objectives: There are limited data on drug-coated balloon (DCB) treatment for de novo diffuse coronary artery disease (CAD). This study aimed to evaluate the clinical impact of DCB-based percutaneous coronary intervention (PCI) in patients with de novo diffuse long CAD.
Methods: We retrospectively included 623 patients with single de novo diffuse CAD (≥ 30mm).
Validation of complex PCI criteria in drug-coated balloon angioplasty.
Clin Res Cardiol
August 2025
Department of Biomedical Sciences, Humanitas University, 20072, Pieve Emanuele, Milan, Italy.
Background: Procedural complexity during percutaneous coronary interventions (PCI) with drug-eluting stent (DES) has been associated with adverse events, especially in case of long and multiple stents implantation.
Objective: This study aims to validate contemporary complex PCI criteria for drug coated balloon (DCB)-based PCI.
Methods: Consecutive patients undergoing DCB angioplasty at 2 Italian centers from 2018 to 2023 were retrospectively enrolled.
Drug-Coated Balloons-Based Intervention for Coronary Artery Disease: The Second Report of Asia-Pacific Consensus Group.
JACC Asia
June 2025
Department of Cardiology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea. Electronic address:
Drug-coated balloons (DCBs) provide a stent-free alternative, reducing risks like stent thrombosis and in-stent restenosis and the need for prolonged dual antiplatelet therapy. Recent studies show that DCBs can be effective and safe across various coronary artery diseases (CADs) when lesions are adequately prepared. Specifically, all coronary lesions are treated using the provisional approach, where active lesion preparation is followed by DCB or drug-eluting stent treatment, depending on the results.
View Article and Find Full Text PDF